The blood group typing market is projected to reach USD 3.12 billion by 2021 from USD 1.95 billion in 2016, at a CAGR of 9.8%. The market is segmented based on product & service, technique, test type, end user, and region.
Based on technique, the market is segmented into PCR-based and microarray techniques, assay-based techniques, massively parallel sequencing, and other techniques. The PCR-based and microarray techniques segment is expected to grow at the highest CAGR during the forecast period. The large share and high growth of this segment can be attributed to the rising prevalence of chronic diseases and increasing R&D activities focused on understanding the molecular basis of blood and antibody-antigen interactions.
Based on the end user, the market is segmented into hospitals, blood banks, clinical laboratories, and other end users. The hospitals end-user segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the increasing awareness on blood donations and their importance, rising number of blood donations, and growing requirement of blood in surgical treatments.
Geographically, the market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW).
Some of the major players in the market are Bio-Rad Laboratories, Inc. (U.S.), Grifols, S.A. (Spain), Immucor, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), Quotient, Ltd. (U.S.), ), Novacyt Group (France), BAG Healthcare GmbH (Germany), Rapid Labs (U.K.), Day medical SA (Switzerland), DIAGAST (France), and AXO Science (France).
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly